Neximmune Cost Of Revenue vs Total Operating Expenses Analysis

NEXI Stock

USD 3.32 0.20 6.41%

Neximmune financial indicator trend analysis is infinitely more than just investigating Neximmune recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Neximmune is a good investment. Please check the relationship between Neximmune Cost Of Revenue and its Total Operating Expenses accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Neximmune. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in interest.

For more detail on how to invest in Neximmune Stock please use our How to Invest in Neximmune guide.

Cost Of Revenue vs Total Operating Expenses

Cost Of Revenue vs Total Operating Expenses Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Neximmune Cost Of Revenue account and Total Operating Expenses. At this time, the significance of the direction appears to have almost identical trend.

The correlation between Neximmune's Cost Of Revenue and Total Operating Expenses is 0.91. Overlapping area represents the amount of variation of Cost Of Revenue that can explain the historical movement of Total Operating Expenses in the same time period over historical financial statements of Neximmune, assuming nothing else is changed. The correlation between historical values of Neximmune's Cost Of Revenue and Total Operating Expenses is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Cost Of Revenue of Neximmune are associated (or correlated) with its Total Operating Expenses. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Total Operating Expenses has no effect on the direction of Cost Of Revenue i.e., Neximmune's Cost Of Revenue and Total Operating Expenses go up and down completely randomly.

Correlation Coefficient

0.91

Relationship Direction	Positive
Relationship Strength	Very Strong

View All Relationships

Cost Of Revenue

Cost of Revenue is found on Neximmune income statement and represents the costs associated with goods and services Neximmune provides. Indirect cost, such as salaries, is not included. In other words, cost of revenue is the total cost incurred to obtain a sale. It is more than the traditional cost of goods sold, since it includes specific selling and marketing activities.

Total Operating Expenses

The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.

Most indicators from Neximmune's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Neximmune current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Neximmune. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in interest.

For more detail on how to invest in Neximmune Stock please use our How to Invest in Neximmune guide.As of now, Neximmune's Selling General Administrative is increasing as compared to previous years. The Neximmune's current Enterprise Value Over EBITDA is estimated to increase to 0.03, while Issuance Of Capital Stock is projected to decrease to 0.00.

	2021	2022	2023	2024 (projected)
Depreciation And Amortization	861.4K	576.7K	1.0M	702.8K
Interest Income	52.5K	664.4K	973.3K	1.0M

Depreciation And Amortization Interest Income

Neximmune fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Net Tangible Assets	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Cash And Short Term Investments	Net Receivables	Common Stock Total Equity	Common Stock Shares Outstanding	Short Term Investments	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Net Invested Capital	Property Plant And Equipment Gross	Total Current Assets
Total Assets		-0.23	0.11	0.96	-0.38	0.69	0.77	-0.63	-0.26	0.07	0.83	0.65	-0.12	0.44	1.0	0.11	0.06	-0.38	0.81	-0.11	0.24	-0.93	0.11	0.88	0.82	1.0
Other Current Liab	-0.23		-0.04	-0.21	-0.44	0.49	-0.29	-0.05	-0.77	0.22	-0.1	0.3	0.99	0.72	-0.25	0.04	0.85	-0.44	-0.3	-0.63	-0.11	0.11	-0.06	0.2	0.23	-0.25
Total Current Liabilities	0.11	-0.04		-0.18	-0.6	-0.16	0.44	0.0	-0.26	0.86	0.29	0.38	-0.06	0.11	0.05	0.13	0.26	-0.54	-0.18	-0.4	0.13	-0.07	1.0	-0.04	0.33	0.09
Total Stockholder Equity	0.96	-0.21	-0.18		-0.21	0.73	0.63	-0.62	-0.19	-0.18	0.74	0.53	-0.1	0.41	0.97	0.07	-0.01	-0.22	0.85	0.0	0.2	-0.9	-0.18	0.88	0.71	0.96
Other Liab	-0.38	-0.44	-0.6	-0.21		-0.46	-0.59	0.07	0.79	-0.76	-0.64	-0.82	-0.48	-0.71	-0.31	0.26	-0.81	1.0	0.09	0.76	-0.37	0.34	-0.58	-0.44	-0.77	-0.35
Net Tangible Assets	0.69	0.49	-0.16	0.73	-0.46		0.42	-0.71	-0.74	0.06	0.64	0.73	0.59	0.89	0.68	0.21	0.55	-0.47	0.48	-0.31	0.22	-0.65	-0.17	0.94	0.8	0.67
Property Plant And Equipment Net	0.77	-0.29	0.44	0.63	-0.59	0.42		-0.49	-0.37	0.54	0.96	0.82	-0.21	0.41	0.73	-0.05	0.13	-0.59	0.27	-0.01	0.72	-0.51	0.44	0.63	0.8	0.75
Net Debt	-0.63	-0.05	0.0	-0.62	0.07	-0.71	-0.49		0.4	-0.1	-0.57	-0.54	-0.14	-0.55	-0.63	-0.7	-0.05	0.04	-0.46	-0.26	-0.32	0.46	-0.01	-0.79	-0.57	-0.62
Retained Earnings	-0.26	-0.77	-0.26	-0.19	0.79	-0.74	-0.37	0.4		-0.59	-0.53	-0.82	-0.82	-0.96	-0.21	-0.07	-0.9	0.79	0.15	0.57	-0.39	0.19	-0.25	-0.6	-0.72	-0.23
Accounts Payable	0.07	0.22	0.86	-0.18	-0.76	0.06	0.54	-0.1	-0.59		0.46	0.65	0.23	0.42	-0.01	-0.02	0.5	-0.73	-0.42	-0.4	0.48	0.08	0.86	0.09	0.5	0.03
Cash	0.83	-0.1	0.29	0.74	-0.64	0.64	0.96	-0.57	-0.53	0.46		0.9	0.0	0.6	0.8	-0.05	0.28	-0.65	0.35	-0.11	0.7	-0.61	0.29	0.79	0.9	0.81
Non Current Assets Total	0.65	0.3	0.38	0.53	-0.82	0.73	0.82	-0.54	-0.82	0.65	0.9		0.38	0.84	0.6	-0.04	0.6	-0.83	0.12	-0.37	0.65	-0.47	0.37	0.77	0.95	0.62
Non Currrent Assets Other	-0.12	0.99	-0.06	-0.1	-0.48	0.59	-0.21	-0.14	-0.82	0.23	0.0	0.38		0.79	-0.15	0.05	0.86	-0.48	-0.23	-0.63	-0.06	0.02	-0.08	0.31	0.32	-0.14
Other Assets	0.44	0.72	0.11	0.41	-0.71	0.89	0.41	-0.55	-0.96	0.42	0.6	0.84	0.79		0.4	0.12	0.82	-0.72	0.1	-0.52	0.34	-0.39	0.09	0.77	0.8	0.41
Cash And Short Term Investments	1.0	-0.25	0.05	0.97	-0.31	0.68	0.73	-0.63	-0.21	-0.01	0.8	0.6	-0.15	0.4		0.11	0.01	-0.32	0.84	-0.07	0.2	-0.93	0.05	0.87	0.78	1.0
Net Receivables	0.11	0.04	0.13	0.07	0.26	0.21	-0.05	-0.7	-0.07	-0.02	-0.05	-0.04	0.05	0.12	0.11		-0.08	0.32	0.23	0.29	-0.16	-0.08	0.14	0.24	-0.02	0.11
Common Stock Total Equity	0.06	0.85	0.26	-0.01	-0.81	0.55	0.13	-0.05	-0.9	0.5	0.28	0.6	0.86	0.82	0.01	-0.08		-0.81	-0.23	-0.79	0.14	-0.11	0.25	0.36	0.52	0.03
Common Stock Shares Outstanding	-0.38	-0.44	-0.54	-0.22	1.0	-0.47	-0.59	0.04	0.79	-0.73	-0.65	-0.83	-0.48	-0.72	-0.32	0.32	-0.81		0.09	0.76	-0.39	0.34	-0.53	-0.45	-0.78	-0.35
Short Term Investments	0.81	-0.3	-0.18	0.85	0.09	0.48	0.27	-0.46	0.15	-0.42	0.35	0.12	-0.23	0.1	0.84	0.23	-0.23	0.09		-0.02	-0.31	-0.91	-0.18	0.65	0.4	0.83
Non Current Liabilities Total	-0.11	-0.63	-0.4	0.0	0.76	-0.31	-0.01	-0.26	0.57	-0.4	-0.11	-0.37	-0.63	-0.52	-0.07	0.29	-0.79	0.76	-0.02		0.29	0.33	-0.38	-0.19	-0.43	-0.1
Other Current Assets	0.24	-0.11	0.13	0.2	-0.37	0.22	0.72	-0.32	-0.39	0.48	0.7	0.65	-0.06	0.34	0.2	-0.16	0.14	-0.39	-0.31	0.29		0.13	0.13	0.29	0.44	0.21
Other Stockholder Equity	-0.93	0.11	-0.07	-0.9	0.34	-0.65	-0.51	0.46	0.19	0.08	-0.61	-0.47	0.02	-0.39	-0.93	-0.08	-0.11	0.34	-0.91	0.33	0.13		-0.06	-0.8	-0.71	-0.93
Total Liab	0.11	-0.06	1.0	-0.18	-0.58	-0.17	0.44	-0.01	-0.25	0.86	0.29	0.37	-0.08	0.09	0.05	0.14	0.25	-0.53	-0.18	-0.38	0.13	-0.06		-0.04	0.33	0.09
Net Invested Capital	0.88	0.2	-0.04	0.88	-0.44	0.94	0.63	-0.79	-0.6	0.09	0.79	0.77	0.31	0.77	0.87	0.24	0.36	-0.45	0.65	-0.19	0.29	-0.8	-0.04		0.87	0.87
Property Plant And Equipment Gross	0.82	0.23	0.33	0.71	-0.77	0.8	0.8	-0.57	-0.72	0.5	0.9	0.95	0.32	0.8	0.78	-0.02	0.52	-0.78	0.4	-0.43	0.44	-0.71	0.33	0.87		0.79
Total Current Assets	1.0	-0.25	0.09	0.96	-0.35	0.67	0.75	-0.62	-0.23	0.03	0.81	0.62	-0.14	0.41	1.0	0.11	0.03	-0.35	0.83	-0.1	0.21	-0.93	0.09	0.87	0.79

Click cells to compare fundamentals

Neximmune Account Relationship Matchups

Neximmune fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	13.7M	11.3M	91.0M	43.1M	8.6M	8.2M
Other Current Liab	1.9M	2.5M	6.2M	7.4M	3.7B	3.9B
Total Current Liabilities	3.0M	27.0M	7.2M	10.3M	5.1M	4.8M
Total Stockholder Equity	10.6M	(15.8M)	83.8M	32.3M	3.5M	3.3M
Net Tangible Assets	(43.0M)	(69.4M)	83.8M	32.3M	37.1M	39.0M
Property Plant And Equipment Net	2.6M	2.9M	4.4M	5.4M	1.4M	1.3M
Net Debt	44.5M	14.1M	(30.3M)	(33.6M)	(3.1M)	(3.0M)
Retained Earnings	(47.7M)	(77.6M)	(127.7M)	(190.2M)	(222.6M)	(211.5M)
Accounts Payable	1.2M	2.8M	1.0M	2.4M	1.3M	1.8M
Cash	9.1M	5.0M	30.3M	34.6M	3.2M	3.0M
Non Current Assets Total	2.7M	2.9M	4.8M	5.7M	3.2M	3.9M
Non Currrent Assets Other	103.6K	23.4K	324.1K	265.0K	1.8M	1.9M
Cash And Short Term Investments	10.1M	5.0M	81.8M	34.6M	4.6M	4.4M
Common Stock Shares Outstanding	900.9K	910.3K	913.2K	962.4K	1.0M	1.9M
Liabilities And Stockholders Equity	13.7M	11.3M	91.0M	43.1M	8.6M	8.2M
Other Current Assets	833.2K	78.5K	99.2K	2.7M	215.2K	204.5K
Other Stockholder Equity	4.7M	8.2M	(90.8B)	222.5M	226.1M	237.4M
Total Liab	3.1M	27.1M	7.3M	10.8M	5.1M	4.8M
Net Invested Capital	(43.0M)	(50.3M)	83.8M	32.3M	3.5M	3.7M
Property Plant And Equipment Gross	2.6M	2.9M	6.7M	5.4M	3.0M	4.1M
Total Current Assets	11.0M	8.4M	86.3M	37.4M	5.4M	5.1M
Net Working Capital	8.0M	(18.6M)	79.1M	27.0M	316.7K	300.9K
Property Plant Equipment	2.6M	2.9M	4.4M	5.4M	6.2M	3.7M

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

When determining whether Neximmune offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Neximmune's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Neximmune Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Neximmune Stock:

How To Invest In Neximmune

Details

Is Neximmune Stock a good investment?

Details

What is Neximmune's Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Neximmune. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in interest.

For more detail on how to invest in Neximmune Stock please use our How to Invest in Neximmune guide.

You can also try the Portfolio Holdings module to check your current holdings and cash postion to detemine if your portfolio needs rebalancing.

Complementary Tools for Neximmune Stock analysis

When running Neximmune's price analysis, check to measure Neximmune's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Neximmune is operating at the current time. Most of Neximmune's value examination focuses on studying past and present price action to predict the probability of Neximmune's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Neximmune's price. Additionally, you may evaluate how the addition of Neximmune to your portfolios can decrease your overall portfolio volatility.

	FinTech Suite Use AI to screen and filter profitable investment opportunities
	Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities
	Transaction History View history of all your transactions and understand their impact on performance
	Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk
	Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges
	Economic Indicators Top statistical indicators that provide insights into how an economy is performing
	Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges
	CEOs Directory Screen CEOs from public companies around the world
	Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
	Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios
	Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk

Is Neximmune's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Neximmune. If investors know Neximmune will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Neximmune listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(30.82)

Return On Assets

(0.71)

Return On Equity

(1.81)

The market value of Neximmune is measured differently than its book value, which is the value of Neximmune that is recorded on the company's balance sheet. Investors also form their own opinion of Neximmune's value that differs from its market value or its book value, called intrinsic value, which is Neximmune's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Neximmune's market value can be influenced by many factors that don't directly affect Neximmune's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Neximmune's value and its price as these two are different measures arrived at by different means. Investors typically determine if Neximmune is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Neximmune's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Neximmune Cost Of Revenue vs Total Operating Expenses Analysis

Cost Of Revenue vs Total Operating Expenses

Cost Of Revenue vs Total Operating Expenses Correlation Analysis

Correlation Coefficient

Cost Of Revenue

Total Operating Expenses

Neximmune fundamental ratios Correlations

Neximmune Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Neximmune fundamental ratios Accounts

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

Complementary Tools for Neximmune Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash And Short Term Investments	+ 1.0	Total Assets
Total Current Assets	+ 1.0	Total Assets
Total Liab	+ 1.0	Total Current Liabilities
Common Stock Shares Outstanding	+ 1.0	Other Liab
Total Current Assets	+ 1.0	Cash And Short Term Investments
Non Currrent Assets Other	+ 0.99	Other Current Liab

Other Assets	- 0.96	Retained Earnings
Total Current Assets	- 0.93	Other Stockholder Equity
Other Stockholder Equity	- 0.93	Cash And Short Term Investments
Other Stockholder Equity	- 0.93	Total Assets
Other Stockholder Equity	- 0.91	Short Term Investments
Common Stock Total Equity	- 0.9	Retained Earnings